Anti Vascular Endothelial Growth Factor (VEGF therapy)

Gazepov, Strahil and Alicov, Funda and Blagadusoska, Gabriela (2024) Anti Vascular Endothelial Growth Factor (VEGF therapy). Knowledge – International Journal, 67 (4). pp. 607-610. ISSN 1857-923X

Text ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF THERAPY).pdf - Published Version Available under License Creative Commons Public Domain Dedication. Download (995kB)

Abstract

Anti-VEGF therapy is a therapy used to treat eye diseases associated with abnormal growth of blood
vessel and their splashing into the retina. Abnormal blood vessels are often occur with wet (neovascular) form of
macular degeneration and other retinal vascular diseases that can lead to serious vision problems and with blindess if
it’s not treated on time. Vascular endothelial growth factor is a protein that is naturally found in the body and
participates in the formation of new blood vessels (angiogenesis).
Angiogenesis isn’t important for proper wound healing, however, the increased VEGF activity will lead to the
formation of new blood vessels that will be pathologically altered and will cause damage to the retina, which can
lead to permanent vision loss. Diseases that are treated with this therapy are the wet form of macular degeneration,
which is one of the various causes of vision loss in older people. In addition to macular degeneration and diabetic
retinopathy can damage blood vessels.
This damage occurs as a results of high blood sugar levels. Retinal vein occlusion also causes vision loss due to
occlusion to the rethinal vein and fluid accumulation.
Vascular entothelial factor increases the risk of developing new abnormal vessels in response to the occlusion. Other
diseases where anti VEGF therapy is used include corneal and choroidal neovascularization and certain types of
retinal dystrophies.
Anti-VEGF-therapy works by inhibiting vascular endothelial factor, that is preventing from binding to receptors on
endothelial cells, cells that line blood vessels, whit that is stopping formation of new abnormal blood vessels. Some
of the most commonly used drugs are: Ranibizumab (Lucentis), Afliberecept (Eylea), Bevacizumab (Avastin).
These drugs are administered in the form of injection directly into the eye – intravitreal injections. These drugs
provide rapid and effective action in the retina. This therapy has minimal side effects.
Keywords: Anti-VEGF therapy, diagnosis, treatment.

Item Type:	Article
Uncontrolled Keywords:	Keywords: Anti-VEGF therapy, diagnosis, treatment.
Subjects:	Medical and Health Sciences > Clinical medicine
Divisions:	Faculty of Medical Science
Depositing User:	Strahil Gazepov
Date Deposited:	18 Dec 2024 09:32
Last Modified:	18 Dec 2024 09:32
URI:	https://eprints.ugd.edu.mk/id/eprint/35265

Actions (login required)

View Item